Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Tacrolimus Monohydrate

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Tacrolimus

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tacrolimus Hydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 68,146Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novaliq Advances NOV05 In FDA-Cleared Phase II Trial
    Novaliq Advances NOV05 In FDA-Cleared Phase II Trial

    26 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260126710784/en/Novaliq-Receives-FDA-IND-Clearance-to-Advance-NOV05-in-a-Phase-II-Clinical-Trial-in-Non-infectious-Anterior-Uveitis

    BUSINESSWIRE
    26 Jan 2026
    Share Share
    Nexus Pharmaceuticals Launches Tacrolimus Injection
    Nexus Pharmaceuticals Launches Tacrolimus Injection

    01 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251201214335/en/Nexus-Pharmaceuticals-Launches-Tacrolimus-Injection

    BUSINESSWIRE
    01 Dec 2025
    Share Share
    Eledon Reveals Initial Results Of Tegoprubart In Type 1 Diabetes
    Eledon Reveals Initial Results Of Tegoprubart In Type 1 Diabetes

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3190482/0/en/Eledon-Reports-Preliminary-Data-from-First-Six-Patients-with-Type-1-Diabetes-Treated-with-Tegoprubart-as-the-Core-Immunosuppressant-Following-Islet-Transplantation-in-Investigator-.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    Eledon Pharma Reveals Q3 2025 Financials & Business Updates
    Eledon Pharma Reveals Q3 2025 Financials & Business Updates

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188645/0/en/Eledon-Pharmaceuticals-Announces-Recent-Business-Highlights-and-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    The API Race Is On — And Fishfa Biogenics Is Setting the Pace!
    The API Race Is On — And Fishfa Biogenics Is Setting the Pace!

    06 Nov 2025

    // PRESS RELEASE

    https://www.fishfabiogenics.com/pharma-api/the-api-race-is-on-and-fishfa-biogenics-is-setting-the-pace/

    PRESS RELEASE
    06 Nov 2025
    Share Share
    Eledon Unveils Tegoprubart Phase 2 Trial Results At Asn Kidney
    Eledon Unveils Tegoprubart Phase 2 Trial Results At Asn Kidney

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183316/0/en/Eledon-Presents-Phase-2-BESTOW-Trial-Results-for-Tegoprubart-for-the-Prevention-of-Rejection-in-Kidney-Transplantation-at-the-American-Society-of-Nephrology-s-Kidney-Week-2025-Annu.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.